Search
Crescent Biopharma Ord Shs
CBIOAdd to Watchlist
14.150USD
-0.220-1.53%
Close 11-13 16:00（ET）
525.53MMarket Cap
LossP/E TTM
Crescent Biopharma Ord Shs (CBIO) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts
Buy
3 Strong Buy
4 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
31.500USD+133.68%
CBIO Analyst Recommendation Trends
In the current month, CBIO has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. CBIO average Analyst price target in the last month is 31.500.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
9
9
9
9
9
9
CBIO Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, CBIO EPS is projected to reach -0.716 in FY2026Q3, following reported EPS of -0.813 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.95
-0.80
-0.72
-0.77
-0.93
Actual
-0.77
-0.81
--
--
--
Surprise
+19.08%
-2.32%
--
--
--
FAQs
What is Crescent Biopharma Ord Shs's expected revenue for the next quarter?
Crescent Biopharma Ord Shs's expected revenue is 312.50K.
What is Crescent Biopharma Ord Shs's price target?
Analysts forecast that Crescent Biopharma Ord Shs's price target is USD 31.50, with the highest forecast at USD 36.00 and the lowest forecast at USD 27.00.
How have Crescent Biopharma Ord ShsCBIO's recent earnings per share performed?
The market expectation was USD -0.81, while Crescent Biopharma Ord ShsCBIO's earnings per share (EPS) for the previous quarter was USD -0.77. EPS for the next quarter is expected at USD -0.72.
What is the analyst rating for Crescent Biopharma Ord Shs?
Based on the ratings of Crescent Biopharma Ord Shs's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.